---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007071"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:21:56.037925+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# HBIO Q3: revenues $20.6M, net loss narrows to $1.2M; Q4 guidance $22.5-$24.5M

## Summary
- Q3 2025 revenues $20.6M (down 6.4% YoY); gross margin 58.4% vs 58.1%.
- Net loss ($1.2M) vs ($4.8M) YoY; adjusted EBITDA $2.0M vs $1.3M.
- Cash from operations $1.1M positive vs ($0.8M) in Q3 2024.
- Company in active discussions to refinance or repay credit agreement in Q4.
- Q4 guidance: revenues $22.5M-$24.5M, gross margin 58%-60%; cites increased demand and backlog.

## SEC filing metadata
- accession: 0001171843-25-007071
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184325007071/0001171843-25-007071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184325007071/f8k_110625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007071
- JSON: https://secwatch.observer/filing/0001171843-25-007071.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.